Zentalis Pharmaceuticals (NASDAQ:ZNTL) Receives Neutral Rating from Wedbush
Wedbush reaffirmed their neutral rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) in a research note issued to investors on Friday morning,Benzinga reports. The brokerage currently has a $4.00 target price on the stock. A number of other research firms have also commented on ZNTL. UBS Group lowered their target price on Zentalis […]
Wedbush reaffirmed their neutral rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) in a research note issued to investors on Friday morning,Benzinga reports. The brokerage currently has a $4.00 target price on the stock. A number of other research firms have also commented on ZNTL. UBS Group lowered their target price on Zentalis […]
